Reperfusion in Patients With Renal Dysfunction After Presentation With ST-Segment Elevation or Left Bundle Branch Block GRACE (Global Registry of Acute Coronary Events) by Medi, Caroline et al.
R
A
o
G
C
A
J
D
S
a
O
S
B
p
M
i
c
R
0
t
r
f
(
a
a
h
f
C
l
O
C
F
P
§

U
a
M
g
a
S
h
P
S
S
S
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 2 , N O . 1 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 8 . 0 9 . 0 1 0eperfusion in Patients With Renal Dysfunction
fter Presentation With ST-Segment Elevation
r Left Bundle Branch Block
RACE (Global Registry of Acute Coronary Events)
aroline Medi, MBBS, FRACP,* Gilles Montalescot, MD, PHD,†
ndrzej Budaj, MD, PHD,‡ Keith A. A. Fox, MB, CHB, FRCP,§
osé Lo´pez-Sendo´n, MD, FACC, Gordon FitzGerald, PHD,¶
avid B. Brieger, MBBS, PHD, FRACP, FACC,* on behalf of the GRACE Investigators
ydney, Australia; Paris, France; Warsaw, Poland; Edinburgh, Scotland; Madrid, Spain;
nd Worcester, Massachusetts
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ackground Few data are available informing the treatment of STE myocardial infarction in the
resence of renal dysfunction.
ethods Patients (N  12,532) from the GRACE (Global Registry of Acute Coronary Events) present-
ng with STE/LBBB were stratiﬁed by renal function and receipt of ﬁbrinolysis, primary percutaneous
oronary intervention (PCI), or neither.
esults As renal function declined, hospital mortality increased and reperfusion decreased (both p 
.001). Compared with no reperfusion, primary PCI was associated with lower hospital mortality in pa-
ients with normal renal function (1.9% vs. 3.7%, p  0.001, adjusted) but no reduction in those with
enal dysfunction (14% vs. 15% for glomerular ﬁltration rate [GFR] 30 to 59 ml/min/1.73 m2; 29% vs. 32%
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te renal dysfunction (adjusted odds ratio: 1.35, 95% conﬁdence interval: 1.01 to 1.80). Primary PCI was
ssociated with increased hospital bleeding and ﬁbrinolysis with increased stroke in all patients. Among
ospital survivors, primary PCI, but not ﬁbrinolysis, was associated with lower mortality for moderate dys-
unction. Both reperfusion strategies were associated with higher mortality for severe dysfunction.
onclusions In STE/LBBB and renal dysfunction, mortality rates are high and reperfusion rates are
ower. In moderate renal dysfunction, primary PCI is associated with mortality reduction at 6 months.
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27enal dysfunction is associated with a significant increase in
ardiovascular risk (1-6), and patients with a history of renal
ysfunction who develop a myocardial infarction have a
oor prognosis (2,7-9). Observational analyses have dem-
nstrated improved survival in patients with renal dysfunc-
ion after revascularization in stable coronary disease (10);
owever, this group consistently manifests lower survival
ates relative to those with intact kidney function (11,12).
hese patients constitute a disproportionately high propor-
ion of individuals who die after myocardial infarction.
ecause patients with renal dysfunction are usually excluded
rom randomized trials of reperfusion therapies (13), there is
lack of both prospective evidence and guideline-based
ecommendations on the treatment of ST-segment eleva-
ion myocardial infarction (STEMI) in the presence of renal
ysfunction.
See page 34
The risks associated with reperfusion therapy are exagger-
ted in patients with renal dysfunction. After percutaneous
oronary intervention (PCI), renal dysfunction has been asso-
iated with a reduction in procedural success and an increase in
ospital and long-term adverse outcomes (14). In addition,
atients with renal dysfunction might be relatively resistant to
he beneficial effects of fibrinolysis and the risk of bleeding
ight be increased (15).
The impact of these unfavorable outcomes relative to the
enefit of emergently re-establishing flow in patients with
cute ST-segment elevation (STE)/left bundle branch block
LBBB) has not been well established. The aim of this study
as to use data from the GRACE (Global Registry of Acute
oronary Events) to describe patterns of reperfusion as well as
utcomes, after receipt or non-receipt of reperfusion therapy
mong a large cohort of patients with STE/LBBB and varying
egrees of renal dysfunction.
ethods
he rationale and methods of the GRACE study have been
reviously published (16,17). A total of 121 hospitals
ocated in 14 countries contributed data to this study from
pril 1999 to June 2007.
tudy population. Data were collected by trained coordina-
ors with a standardized case report form. Demographic
haracteristics, medical history, presenting symptoms, bio-
hemical and electrocardiographic findings, treatment prac-
ices, and a variety of hospital outcome data were collected.
n-hospital management of patients was left to the discre-
ion of the investigating physicians. Standardized defini-
ions for all patient-related variables and clinical diagnoses
ere used (16). Where required, study investigators received
pproval from their local hospital ethics or institutional
eview board for the conduct of this study. This analysis was westricted to patients presenting with STEMI/LBBB, de-
ned by the presence of new STE0.1 mV in 2 contiguous
eads or new LBBB seen on the index or qualifying
lectrocardiogram. Patients with STEMI/LBBB who were
ransferred from hospitals not involved in the GRACE
tudy were excluded. Patients with contraindications to
ither fibrinolytic therapy or PCI were also excluded.
Patients were stratified into groups according to glomer-
lar filtration rate (GFR), calculated by the Modification of
iet in Renal Disease method (18). Groups consisted of
ormal kidney function (GFR 60 ml/min/1.73 m2),
oderate kidney function (GFR 30 to 59 ml/min/1.73 m2),
nd severe renal dysfunction (GFR 30 ml/min/1.73 m2).
ach GFR group was analyzed according to hospital treat-
ent received of reperfusion (either primary PCI or fibri-
olysis) or no reperfusion, excluding patients who received
oth primary PCI and fibrinolysis during their hospital stay.
utcomes included mortality (both in hospital and at 6
onths after discharge) and hospital major adverse events of
ardiac failure/acute pulmonary
dema, cardiac arrest/ventricular
brillation, recurrent ischemia, re-
urrent myocardial infarction,
troke, and major bleeding (On-
ine Appendix).
tatistical analysis. Dichotomous
atient outcomes were compared
cross GFR groups with the
antel-Haenszel linear trend
est and across reperfusion
roups with the chi-square test.
or continuous variables, trend
cross GFR groups was assessed
y linear regression.
Adjusted outcome odds ratios
ORs) were generated with multiple logistic regression.
ospital and 6-month mortality were adjusted for GRACE
isk score (variables were age, Killip class, systolic blood
ressure, ST-segment deviation, cardiac arrest on presenta-
ion, serum creatinine, positive initial cardiac markers, and
ulse) (19). Six-month mortality (from hospital discharge to
months) was also adjusted for age, systolic blood pressure,
reatinine concentration, positive initial markers, pulse,
istory of myocardial infarction, history of coronary heart
ailure, and ST-segment depression (20).
esults
enal dysfunction was seen in 3,450 (28%) of the 12,532
atients presenting with STEMI/LBBB, comprising 2,982
24%) with moderate kidney function and 468 (3.7%) with
evere renal dysfunction. Patients with renal dysfunction
ere sicker than those without renal disease (Table 1). They
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
GFR  glomerular filtration
rate
LBBB  left bundle branch
block
OR  odds ratio
PCI  percutaneous
coronary intervention
STE  ST-segment elevation
STEMI  ST-segment
elevation myocardial
infarctionere older and had higher rates of prior myocardial infarc-
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28ion and congestive heart failure and a greater prevalence of
ardiovascular risk factors. They were also more compro-
ised on presentation, with a lower systolic blood pressure
nd higher Killip class.
Table 1. Baseline Characteristics of Patients With ST-Segment Elevation o
Normal Function
(n  9,082)
Demographic characteristics
Male (%) 77
Age, median (IQR), yrs 60 (51–70)
Weight, median (IQR), kg 77 (68–87)
Admission characteristics
Killip class (%) II to IV 12.5
Pulse, median (IQR), beats/min 75 (64–88)
SBP, median (IQR), mm Hg 131 (119–150)
Creatinine, median (IQR), mg/dl 0.9 (0.8–1.1)
GRACE risk score, median (IQR) 134 (116–155)
Medical history (%)
Myocardial infarction 17
Congestive cardiac failure 3.3
Smoker 66
Diabetes 17
Hypertension 44
Hyperlipidemia 38
Peripheral arterial disease 4.6
Infarct territory
Anterior (includes anterolateral) 42.9
Inferior (includes inferolateral) 47.0
Lateral 5.2
LBBB 4.9
N 12,532.
GRACE Global Registry of Acute Coronary Events; IQR interquartile range; LBBB left bund
Figure 1. Incidence of Hospital Adverse Outcomes and 6-Month Death, Str
p  0.001 for linear trend in all outcomes except recurrent myocardial infarcti
the most recent version of the case report form (n  6,211). †Among 8,841 su
fusion. APO  acute pulmonary edema; CCF  congestive cardiac failure; VF  ventPatients with renal dysfunction experienced worse out-
omes (Fig. 1). Hospital mortality rates increased signifi-
antly as GFR decreased (p  0.001), exceeding 30% in
atients with severe renal dysfunction. Approximately one-
B Stratified According to Renal Function
erate Dysfunction
(n  2,982)
Severe Dysfunction
(n  468) p Value
55 47 0.001
74 (65–81) 77 (68–84) 0.001
74 (64–84) 70 (60–80) 0.001
30.0 43.3 0.001
80 (66–96) 85 (68–100) 0.001
130 (110–150) 120 (100–140) 0.001
1.4 (1.2–1.5) 2.6 (2.2–3.7) 0.001
165 (145–188) 188 (164–218) 0.001
26 34 0.001
13 28 0.001
47 38 0.001
26 41 0.001
63 74 0.001
38 36 0.45
8.9 18 0.001
41.6 36.1 0.001
39.6 39.3
5.5 4.1
13.2 20.5
h block; SBP systolic blood pressure.
by Renal Function
I) p  0.23. *Data on recurrent myocardial infarction were collected only in
s to hospital discharge with 6-month follow-up and complete data on reper-r LBB
Modatified
on (M
rvivorricular ﬁbrillation.
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29hird of patients with renal dysfunction experienced pulmo-
ary edema or heart failure after infarction, 3 times the rate
n patients with normal kidney function. The rate of cardiac
rrest or ventricular fibrillation exceeded 20% in patients at
he lowest stratum of kidney function. Patients with renal
ysfunction demonstrated a significantly higher rate of
ajor bleeding. Six-month mortality was notably higher
cross all treatment groups as GFR declined (p  0.001).
eperfusion and renal dysfunction. Despite their higher risk
haracteristics and poorer outcomes, patients with renal
ysfunction were less likely to receive reperfusion therapy.
eperfusion was received by 62% of patients with normal
enal function, by 48% with moderate function, and by 31%
ith severe dysfunction. Within each stratum of renal
unction, reperfusion therapy was typically offered to lower-
isk patients versus those who did not receive reperfusion
Table 2). Patients who received fibrinolysis and proceeded
Table 2. Comparison Between Reperfusion and No Reperfusion Patients by
Normal Function*
Reperfusion
(n  5,630)
No Reperfusio
(n  3,452)
Demographic characteristic
Men (%) 80 73
Age, median (IQR), yrs 59 (51–68) 63 (53–73)
Weight, median (IQR), kg 77 (69–87) 76 (67–86)
Admission characteristic
Killip class (%) II to IV 11 15
Pulse, median (IQR), beats/min 74 (63–86) 78 (66–90)
Median systolic blood pressure, mm Hg (IQR) 130 (117–150) 135 (120–150
Median creatinine, mg/dl (IQR) 1.0 (0.8–1.1) 0.9 (0.8–1.1)
GRACE risk score (IQR) 132 (115–151) 137 (117–160
Medical history (%)
Myocardial infarction 13 24
CHF 1.6 6.2
Smoker 69 62
Diabetes 15 21
Hypertension 40 50
Hyperlipidemia 37 41
PAD 3.6 6.2
*p  0.001 for all glomerular filtration rate (GFR) 60 ml/min/1.73 m2, except p  0.003 for weig
hyperlipidemia, p 0.001 for weight, p 0.004 for creatinine.
CHF congestive heart failure; PAD peripheral arterial disease; other abbreviations as in Tabl
Table 3. Reperfusion Strategies and Baseline GFR, Showing Median GRAC
Reperfusion (%) Normal Renal Function
Primary PCI (n  3,397) 79 (136, 1.9%)
Fibrinolysis (n  3,795) 77 (133, 3.1%)
Both ﬁbrinolysis and PCI (n  664)* 83 (134, 3.8%)
Neither (n  5,340) 65 (140, 3.7%)
*552, 105, and 7 patients in the 3 glomerular filtration rate (GFR) groups.GRACE Global Registry of Acute Coronary Events; PCI percutaneous coronary intervention.o rescue angioplasty constituted 5% of the STEMI/LBBB
opulation and did not differ significantly from the overall
ohort. Impaired renal function was not associated with a
reater likelihood of receiving rescue PCI. The proportion
f patients in each GFR group comprising this population
ogether with their median GRACE risk score and hospital
eath rates are presented in Table 3.
enal dysfunction and impact on hospital mortality. In pa-
ients with normal renal function, primary PCI was associ-
ted with lower mortality rates than either fibrinolysis or no
eperfusion (Table 4). Among patients with renal dysfunc-
ion, primary PCI was associated with numerically lower
ortality rates than in patients not receiving reperfusion.
umbers with renal dysfunction were relatively small (es-
ecially severe renal dysfunction), and the differences were
ot statistically significant. Fibrinolysis was not associated
ith lower mortality than nonreperfusion among patients
l Function
Moderate Dysfunction† Severe Dysfunction
p Value
Reperfusion
(n  1,415)
No Reperfusion
(n  1,567)
Reperfusion
(n  147)
No Reperfusion
(n  321)
57 54 52 46 0.23
71 (62–79) 76 (69–83) 73 (63–81) 78 (71–85) 0.001
75 (65–85) 73 (63–83) 74 (63–80) 70 (58–80) 0.02
25 34 39 45 0.22
76 (62–90) 82 (70–100) 80 (64–100) 89 (71–102) 0.01
30 (110–148) 132 (115–150) 120 (100–140) 120 (100–140) 0.35
1.4 (1.2–1.5) 1.4 (1.2–1.6) 2.7 (2.3–4.5) 2.5 (2.2–3.6) 0.02
61 (143–183) 170 (148–191) 179 (156–211) 191 (168–218) 0.06
17 34 30 35 0.34
5.1 19 17 34 0.001
52 43 38 38 0.99
22 29 34 44 0.05
60 66 75 73 0.65
38 38 37 35 0.83
7.0 11 16 19 0.52
 0.001 for all GFR 30 to 59 ml/min/1.73 m2, except p  0.04 for gender, p  0.73 for history of
Score (in Parentheses), and Hospital Death (in Parentheses)
rate Renal Dysfunction Severe Renal Dysfunction p Value
18 (169, 13.6%) 2 (190, 29.2%) 0.001
21 (160, 13.3%) 2 (186, 32.4%)
16 (157, 10.5%) 1 (174, 42.9%)
29 (171, 15.1%) 6 (192, 31.5%)Rena
n
) 1
) 1
ht. †pE Risk
Mode
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30ith normal renal function or severe renal dysfunction but,
fter adjustment, was associated with higher mortality
mong patients with moderate renal dysfunction.
troke rates and major bleeding. Fibrinolysis, but not pri-
ary PCI, was associated with an increased rate of stroke in
ll patients, significant for those with normal renal function
Table 5). Major bleeding occurred more frequently among
ll patients receiving reperfusion therapy. Differences in
leeding rates were statistically significant for patients with
ormal and moderate renal dysfunction undergoing PCI
nd for patients with normal renal function receiving
brinolysis (Table 5).
ost-discharge mortality. Among patients surviving to hos-
ital discharge, receipt of reperfusion was associated with
Table 4. Hospital and 6-Month Post-Discharge Mortality Comparing Primar
Primary PCI
(n  3,395)
Fibrinolysis
(n  3,790)
Neither
(n  5,332)
Hospital mortality
Normal renal function
268/9,076 (3.0%)
1.9%
51/2,699
3.1%
91/2,928
3.7%
126/3,449
Moderate renal dysfunction
426/2,974 (14.3%)
13.6%
85/624
13.3%
105/788
15.1%
236/1,562
Severe renal dysfunction
146/467 (31.3%)
29.2%
21/72
32.4%
24/74
31.5%
101/321
All patients
840/12,517 (6.7%)
157/3,395
4.6%
220/3,790
5.8%
463/5,332
8.7%
6-month mortality
Normal renal function
160/6,635 (2.4%)
32/1,894
1.7%
36/2,236
1.6%
92/2,505
3.7%
Moderate renal dysfunction
161/1,977 (8.1%)
14/398
3.5%
26/555
4.7%
121/1,024
11.8%
Severe renal dysfunction
41/229 (17.9%)
8/36
22.2%
10/43
23.3%
23/150
15.3%
All patients
362/8,841 (4.1%)
54/2,328
2.3%
72/2,834
2.5%
236/3,679
6.4%
*Adjusted for GRACE risk score (Granger et al. [19] for hospital and Eagle et al. [20] for 6-month dea
CI confidence interval; OR odds ratio; STE ST-segment elevation; other abbreviations as in
Table 5. Incidence of Hospital Stroke
and Major Bleeding Stratified by Renal Function
Normal Renal
Function
(n  8,937)
Moderate Renal
Dysfunction
(n  2,924)
Severe Renal
Dysfunction
(n  459)
Primary PCI (n  3,350)
Stroke, % 0.2 (p 0.04) 1.3 (p 0.71) 1.4 (p 0.77)
Major bleeding, % 2.7 (p 0.001) 6.8 (p 0.001) 7.3 (p 0.23)
Fibrinolysis (n  3,723)
Stroke, % 1.2 (p 0.004) 1.7 (p 0.53) 2.7 (p 0.64)
Major bleeding, % 1.9 (p 0.02) 3.4 (p 0.11) 8.2 (p 0.12)
No reperfusion (n  5,247)
Stroke, % 0.6 1.3 1.9
Major bleeding, % 1.4 2.5 4.2
N 12,320. p values are given with “no reperfusion” as the reference group and are adjusted for
GRACE risk score.pAbbreviations as in Table 3.ower mortality for the overall STE/LBBB population.
fter stratifying for renal function, this benefit was seen
mong patients with normal renal function receiving fibri-
olysis (adjusted OR: 0.65, 95% confidence interval: 0.43 to
.00) and in those with moderate dysfunction receiving
rimary PCI (adjusted OR: 0.41, 95% confidence interval:
.22 to 0.75). Mortality rates remained high for patients
ith severe renal dysfunction regardless of receipt of reper-
usion, and reperfusion was associated with worse outcome.
omparison of adjusted ORs for mortality after primary
CI and fibrinolysis relative to no reperfusion for each GFR
roup is shown in Table 4.
iscussion
his large multinational, multicenter analysis of over 12,000
atients presenting with STE/LBBB shows that patients
ith moderate renal dysfunction have an approximately
-fold higher early mortality and that those with severe
enal dysfunction have a mortality risk of approximately
0-fold that of patients with normal renal function. These
ata are consistent with other observational studies in
atients with renal dysfunction (4,12,21,22). In our analysis,
e found that reperfusion was offered to patients less
requently as renal function deteriorated. This risk-averse
ehavior is consistent with that described among physicians
electing patients with an acute coronary syndrome (ACS)
or coronary angiography (23). The reasons for this are not
lear and might reflect both a judgment that “active”
reatment with reperfusion has an unfavorable risk/benefit
and Fibrinolysis With No Reperfusion
usted* OR (95% CI)
ary PCI vs. Neither
Adjusted* OR (95% CI)
Fibrinolysis vs. Neither
Adjusted* OR (95% CI)
Primary PCI vs. Fibrinolysis
4 (0.38–0.78)
0.001
1.06 (0.78–1.44)
p 0.73
0.51 (0.35–0.76)
p 0.001
8 (0.64–1.20)
0.41
1.35 (1.01–1.80)
p 0.04
0.65 (0.45–0.93)
p 0.02
0 (0.41–1.55)
0.51
1.11 (0.57–2.14)
p 0.77
0.72 (0.31–1.72)
p 0.46
2 (0.57–0.90)
0.004
1.20 (0.98–1.47)
p 0.07
0.59 (0.46–0.77)
p 0.001
7 (0.43–1.04)
0.07
0.65 (0.43–1.00)
p 0.05
1.03 (0.63–1.69)
p 0.91
1 (0.22–0.75)
0.004
0.70 (0.43–1.12)
p 0.14
0.58 (0.29–1.16)
p 0.13
3 (1.01–7.36)
0.05
2.96 (1.12–7.83)
p 0.03
0.92 (0.29–2.90)
p 0.89
0 (0.44–0.84)
0.003
0.73 (0.54–0.98)
p 0.04
0.83 (0.57–1.20)
p 0.33
for GFR level in model combining all GFR levels.
1, 2, and 3.y PCI
Adj
Prim
0.5
p
0.8
p
0.8
p
0.7
p
0.6
p
0.4
p
2.7
p
0.6
p
th) androfile in the context of a high prevalence of comorbidities;
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31n increase in the proportion of patients with renal dysfunc-
ion who have a delayed or an atypical (24) presentation; a
igher proportion who are ineligible for reperfusion therapy
ue to contraindications (24); and the absence of random-
zed controlled evidence in this population to support an
ggressive approach.
In our nonrandomized cohort, reperfusion with fibrino-
ytic therapy was not associated with a mortality reduction
n our population with renal impairment. Indeed, after
djustment, hospital mortality was greater for patients with
oderate renal dysfunction receiving fibrinolysis. This was
ffset by a trend toward reduced mortality in this population
t 6 months. Nonetheless, the lack of appreciable benefit of
brinolysis in this cohort is an unsettling observation,
ecause it is readily available in most clinical settings and
s the most common form of reperfusion therapy. As
xpected, there was a numerically greater incidence of stroke
mong patients receiving fibrinolytic therapy regardless of
enal function.
Consistent with randomized trial evidence, primary PCI
as associated with the lowest hospital mortality rates
mong patients with normal renal function. There was no
ignificant reduction in mortality after primary PCI ob-
erved among patients with renal dysfunction, although this
ight reflect a type II error because of the smaller number
f patients with renal dysfunction. The absolute reduction
f approximately 2% in mortality among renal dysfunction
atients receiving primary PCI relative to those not offered
eperfusion was comparable to that observed among patients
ith normal renal function.
As expected, any potential clinical benefit of primary
CI in patients with renal dysfunction was accompanied
y an excess in complications. Percutaneous angiography
r angioplasty carries an increased risk in the average patient
ith renal dysfunction, who is already at greater risk of
troke due to a high incidence of cerebrovascular disease and
ore advanced age, higher procedural risk due to frequent
eft ventricular dysfunction, and increased risk of major
leeding (25).
An increase in the likelihood of stroke after primary PCI
as not observed in our cohort, but we did observe a
ignificant increase in major bleeding. Recent studies high-
ight the prognostic importance of major bleeding in pa-
ients with ACS (26), and it is conceivable that bleeding
vents might have attenuated the mortality benefit that
ould otherwise have accompanied the rapid establishment
f coronary artery patency in our cohort. For primary PCI to
ecome a clearly superior treatment option in patients with
enal dysfunction, strategies to reduce bleeding are required.
his includes using a radial rather than femoral artery
pproach for coronary intervention to reduce the risk of
ocal vascular complications (27), use of appropriately dose-
djusted anticoagulant therapies such as low-molecular-
eight heparin (28,29), and the use of a direct thrombin mnhibitor such as bivalirudin instead of intravenous unfrac-
ionated heparin during PCI (30,31).
Primary PCI was associated with lower mortality among
oderate renal dysfunction patients at 6 months. This
allies with an earlier observation on revascularization in
atients with coronary heart failure, where no in-hospital
enefit was seen but a clear long-term benefit was evident
or survivors to discharge (32). This also supports previous
bservations of reduced 2- and 3-year mortality rates
10,33) in patients with renal dysfunction and stable isch-
mic heart disease after revascularization.
We did not find a positive association between reperfu-
ion and 6-month outcomes among patients with severe
enal dysfunction. Indeed, a significant association with
arm was identified. This should be interpreted with cau-
ion, given the small size of this cohort relative to those with
reater retention of renal function. However, the striking
ortality rate in this cohort was an important observation,
nd our data suggest that, in patients with severe renal
ysfunction, coexisting serious morbidities might over-
helm the intermediate-term prognostic benefit of emer-
ency reperfusion after acute myocardial infarction
trengths and study limitations. The GRACE registry is a
ulticenter prospective study including unselected patients
ith ACS; thus it provides a wealth of information on
reatments and outcomes in clinical practice. Whereas
egistry studies are subject to potential biases, they are
aluable for examining real-world practice patterns, partic-
larly among populations not well-represented in random-
zed clinical trials. In this analysis, patients with low GFR
re rare (3.7% of STE/LBBB patients), with only 31%
eceiving reperfusion. However, an unselected cohort of 468
atients with low GFR represents a large patient sample
elative to other studies. Nonetheless, our ability to gener-
lize about the benefit or harm of reperfusion for these
atients is limited. Although important information on
reatment and outcomes of patients with renal dysfunction
s available from GRACE, there are likely to be unrecog-
ized biases, both in patient selection for reperfusion and
he method of reperfusion. We have not reported the
ncidence of new-onset acute renal impairment requiring
ialysis, because this information was not available from the
egistry. Additionally, the data were not controlled for
rognostically important medications known to be under-
sed in patients with renal dysfunction.
onclusions
enal dysfunction is common in patients presenting with
TE/LBBB and is associated with a lower likelihood of
mergency revascularization and significantly higher mor-
ality and morbidity. After adjustment, primary PCI was
ssociated with a lower long-term mortality in patients with
oderate renal dysfunction, tempered by an increase in
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32ajor hospital bleeding. Fibrinolysis was associated with
ncreased hospital mortality in patients with moderate renal
ysfunction but no excess in long-term mortality. Fibrino-
ysis was also associated with an increase in stroke in all
FR strata. Long-term mortality rates remain high in all
atients with severe renal dysfunction. Our data suggest
hat randomized trials prospectively evaluating the rela-
ive benefits of method of reperfusion should actively
nclude patients with renal dysfunction. In the meantime,
fforts should be directed toward reducing major bleeding
omplications in renally impaired patients undergoing
rimary PCI.
cknowledgments
he authors thank the physicians and nurses participating in
RACE and Sophie Rushton-Smith, PhD, for providing
ditorial assistance.
eprint requests and correspondence: Dr. David B. Brieger,
oncord Repatriation General Hospital, Coronary Care Unit,
evel 3, Multi Building, Hospital Road, Concord, NSW Australia
139. E-mail: davidb@email.cs.nsw.gov.au.
EFERENCES
1. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency
as a predictor of cardiovascular outcomes and the impact of ramipril:
the HOPE randomized trial. Ann Intern Med 2001;134:629–36.
2. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications
of abnormalities in renal function in patients with acute coronary
syndromes. Circulation 2002;106:974–80.
3. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine
concentration is a predictor of cardiovascular risk in essential hyper-
tension. Arch Intern Med 2001;161:886–91.
4. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of
incident myocardial infarction and all-cause and cardiovascular disease
mortality in middle-aged men and women form the general population.
Eur Heart J 2006;27:1245–50.
5. Go AS, Lo JC. Epidemiology of non dialysis-requiring chronic kidney
disease and cardiovascular disease. Curr Opin Nephrol Hypertens
2006;15:296–302.
6. Martinez-Vera A, Salvado E, Bardaji A, et al. Silent cerebral white
matter lesions and their relationship with vascular risk factors in
middle-aged predialysis patients with chronic kidney disease. Am J
Kidney Dis 2006;47:241–50.
7. Afshinnia F, Ayazi P, Chadow HL. Glomerular filtration rate on
admission independently predicts short term in-hospital mortality after
acute myocardial infarction. Am J Nephrol 2006;26:408–14.
8. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between
renal dysfunction and cardiovascular outcomes after myocardial infarc-
tion N Engl J Med 2004;351:1285–95.
9. Walsh CR, O’Donnell CJ, Camargo CA, Guigliano RP, Lloyd-Jones
DM. Elevated serum creatinine is associated with 1-year mortality after
acute myocardial infarction. Am Heart J 2002;144:1003–11.
0. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson
ML, Ghali WA. Survival after coronary revascularization among
patients with kidney disease. Circulation 2004;110:1890–5.
1. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney
disease with clinical outcomes after coronary revascularization: the
Arterial Revascularization Therapies Study (ARTS). Am Heart J
2005;149:512–9.2. Szczech LA, Best PJ, Crowley E, et al. Outcomes of patients with
chronic renal insufficiency in the bypass angioplasty revascularization
investigation. Circulation 2002;105:2253–8.
3. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation
of renal disease in randomized controlled trials of cardiovascular
disease. JAMA 2006;296:1377–84.
4. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H,
Palacios IF. Are patients with renal failure good candidates for
percutaneous coronary revascularization in the new device era? Circu-
lation 2000;102:2966–72.
5. Newsome BB, Warnock DG, Kiefe CI, et al. Delay in time to receipt
of thrombolytic medication among Medicare patients with kidney
disease. Am J Kidney Dis 2005;46:595–602.
6. Investigators TG. Rationale and design of the GRACE (Global
Registry of ACute Coronary Events) project: a multinational registry of
patients hospitalized with acute coronary syndromes. Am Heart J
2001;141:190–9.
7. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics,
management practices, and in-hospital outcomes of patients hospital-
ized with acute coronary syndromes in the Global Registry of Acute
Coronary Events (GRACE). Am J Cardiol 2002;90:358–63.
8. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the
modification of diet in renal disease formula for estimating GFR with
special emphasis on calibration of the serum creatinine assay. Am J
Kidney Dis 2004;44:84–93.
9. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital
mortality in the Global Registry of Acute Coronary Events. Arch
Intern Med 2003;163:2345–53.
0. Eagle KA, Lim MJ, Budaj A, et al. A robust prediction model for
all forms of acute coronary syndromes: estimating the risk of
in-hospital death and myocardial infarction in the Global Registry
of Acute Coronary Events Registry. J Am Coll Cardiol 2003;41:
353A.
1. McCullough PA, Soman SS, Shah SS, et al. Risks associated with renal
dysfunction in patients in the coronary care unit. J Am Coll Cardiol
2000;36:679–84.
2. Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality
after myocardial infarction in patients with advanced renal dysfunction.
Am J Kidney Dis 2001;37:1191–200.
3. Fox KAA, Anderson FAJ, Dabbous OH, et al. Intervention in acute
coronary syndromes: do patients undergo intervention on the basis of
their risk characteristics? The Global Registry of Acute Coronary
Events (GRACE). Heart 2007;93:177–82.
4. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical
characteristics of dialysis patients with acute myocardial infarctions in
the United States: a collaborative project of the United States Renal
Data System and the National Registry of Myocardial Infarction.
Circulation 2007;116:1465–72.
5. Attallah N, Yassine L, Fisher K, Yee J. Risk of bleeding and restenosis
among chronic kidney disease patients undergoing percutaneous coro-
nary intervention. Clin Nephrol 2005;64:412–8.
6. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity
account for the excess mortality in patients with major bleeding in acute
myocardial infarction? Circulation 2008;116:2793–801.
7. Agostoni P, Biondi-Zoccai GGL, Benedictis MLD, et al. Radial
versus femoral approach for percutaneous coronary diagnostic and
interventional procedures: systematic overview and meta-analysis of
randomized trials. J Am Coll Cardiol 2004;44:349–56.
8. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus
unfractionated heparin in elective percutaneous coronary intervention.
N Engl J Med 2006;355:1006–17.
9. Dumaine R, Borentain M, Bertel O, et al. Intravenous low-molecular-
weight heparins compared with unfractionated heparin in percutaneous
coronary interventions: quantitative review or randomized trials. Arch
Intern Med 2007;167:2423–30.
0. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provi-
sional glycoprotein IIb/IIIa blockade compared with heparin and
planned glycoprotein IIb/IIIa blockade during percutaneous coronary
intervention. JAMA 2003;289:853–63.
33
3
K
t
S
F
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 , 2 0 0 9
J A N U A R Y 2 0 0 9 : 2 6 – 3 3
Medi et al.
Reperfusion and Renal Dysfunction in ACS
331. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on
30-day mortality and clinical outcomes in patients with acute coronary
syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol
2007;49:1362–8.
2. Steg PG, Lopez-Sendon J, Loez de Sa E, et al. External validity of clinical
trials in acute myocardial infarction. Arch Intern Med 2007;167:68–73.
3. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis
of long-term survival after revascularization in patients with chronic
kidney disease presenting with acute coronary syndromes. Am J Cardiol
2003;92:509–14. vey Words: fibrinolysis  percutaneous coronary interven-
ion  renal dysfunction  left bundle branch block 
T-segment elevation.
APPENDIX
or a list of standardized definitions for GRACE, please see the online
ersion of this article.
